Close

Needham & Company Upgrades Seattle Genetics (SGEN) to Buy; Could Be Next Large Cap Drug Co.

February 12, 2014 7:43 AM EST Send to a Friend
Needham & Company upgraded Seattle Genetics (NASDAQ: SGEN) from Hold to Buy with a price target of $60 in transferred ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login